Member Info for Amonk84

The average grant through NIH is $500k and Tils scored high on the grant scale.
So that's extremely positive for moving this through phase 2 trails.

Frag.

I also feel that that is what is going on and with the sale of the inferior product Oncotype for $2.8bn last year. The mcap for the split Co could really be anywhere from $200mn to $2.8bn

Extract from Orgenesis' EOY report December 2019. It all seems very familiar....

CGT Biotech Platform

Business Strategy

Our CGT Biotech Platform consists of: (a) POCare Therapeutics, a pipeline of licensed CGTs, anti-viral and proprietary scientific know-how; (b) POCare Technologies, a suite of proprietary and in-licensed technologies which are engineered to create customized processing systems for affordable point-of-care therapies; and (c) a POCare Network, a collaborative, international ecosystem of leading research institutions and hospitals committed to clinical development and supply of CGTs at the point-of-care ("POCare Network"). By combining science, technologies and a collaborative network, we believe that we are able to identify the most promising new autologous therapies and provide a pathway for them to reach patients more quickly, more efficiently and in a scalable way, thereby unlocking the power of cell and gene therapy for all patients. Autologous therapies are produced from a patient's own cells, instead of mass-cultivated donor-cells, or allogeneic cells. Allogeneic therapies are derived from donor cells and, through the construction of master and working cell banks, are produced on a large scale. Autologous therapies are derived from the treated patient and manufactured through a defined protocol before re-administration and generally demand a more complex supply chain. Currently with the CGT market relying heavily on production and supply chain of manufacturing sites, we believe our CGT Biotech Platform may help overcome some of the development and supply challenges with bringing these therapies to patients.

In pursuit of this focus, we have been forming key strategic relationships with leading research institutions and hospitals around the world. We are also licensing breakthrough technologies that complement our offerings and support our model. As a result, we believe that we now have significant expertise and capabilities across a wide range of therapies and supporting technologies, ranging from Tumor Infiltrating Lymphocytes ("TILs") to CAR-T and CAR-NK, from dendritic cell technologies to exosomes and bioxomes, to viral vectors and much more. These capabilities have enabled us to launch an aggressive push into a wide array of promising new potential therapies.

We are developing an efficient and streamlined organization, whereby we are able to share both costs and revenues with our partners in order to avoid the historically high development costs associated with CGT drug development. We believe we have developed a truly unique model with the ability to cost-effectively develop and produce CGTs at scale, which we believe has the potential to transform the CGT industry.

Totally agree with your outlook here Alexa191.

I am heavily invested here and continue to average down but I do feel like we will start to climb with the EOY results and it wouldn't surprise me if AZ made an offer.

Bump

It speaks volumes.

.

Dr. David Sidransky - A director of Orgenesis...

Dr. Sidransky has served as a director since his appointment on July 18, 2013. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine's Department of Otolaryngology and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the John Hopkins University School of Medicine. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world in the field of oncology during the past decade, with over 460 peer reviewed publications. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. Dr. Sidransky has served as Vice Chairman of the board of directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is serving, or has served on, the scientific advisory boards of MedImmune, LLC, Roche, Amgen Inc. and Veridex, LLC (a Johnson & Johnson diagnostic company),

I've either painted a monet with my connecting dots or a Picasso. Either one, I feel, has massive value.

The following dated 19 February 2020

Orgenesis Inc (NASDAQ:ORGS) announced a collaboration with Johns Hopkins University to utilize its point-of-care platform to develop and supply gene therapies and technologies.

The company’s POCare cell therapy platform is designed to advance the development of Advanced Therapy Medicinal Products — medicines based on genes, tissues or cells — through collaborations and in-licensing with other companies.

The following is the official announcement of the collaberation from Orgenesis' Annual report dated 31 December 2019.

Collaboration Agreement with Hemogenyx Pharmaceuticals Plc

On October 18, 2018, we entered into a collaboration agreement with Hemogenyx to collaborate on the development and commercialization of Hemogenyx's Human Postnatal Hemogenic Endothelial (Hu-PHEC) technology, a cell replacement product candidate that is being designed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient.

Collaboration Agreement with Immugenyx, LLC

On October 16, 2018, we entered into a collaboration agreement with Immugenyx, LLC ("Immugenyx"), a wholly owned subsidiary of Hemogenyx Pharmaceuticals Plc ("Hemogenyx"), to collaborate with us to further the development and commercialization of its advanced hematopoietic chimeras, which is a new type of humanized mouse with a functional human immune system that is being developed by Immugenyx as an in vivo platform for disease modelling, drug and cell therapy development.

The following extract is taken from Orgenisis' quarterly report dated 31 March 2020. This colaberation is very much still in play and simingly looking to be quite profitable with the patents granted within Europe for the Hu-PHEC treatments.

Hemogenyx Pharmaceuticals PLC.

As described in Note 12 to the financial statements of December 31, 2019, on October 18, 2018, the Company and Hemogenyx Pharmaceuticals PLC., a corporation with its registered office in the United Kingdom, and Hemogenyx-Cell, a corporation with its registered office in Belgium, and is engaged in the development of cell replacement bone marrow therapy technology (“H-Cell” and, collectively with the Company, “Hemo”), entered into a Collaboration Agreement (the “Hemo agreement”) pursuant to which the parties will collaborate in the funding of the continued development of and commercialization of, the Hemo technology via the Hemo group companies. Pursuant to the Hemo agreement, the Company and Hemogenyx LLC (“Hemo-LLC”) (a wholly owned USA subsidiary of Hemo), entered into a loan agreement. During the quarter ended March 31, 2020, the Company advanced an additional $0.25 million under the loan agreement which was charged to expenses under ASC 730-10-50 and 20-50 and presented as research and development costs.
14
Immugenyx LLC
As described in Note 12 to the financial statements as of December 31, 2019, on October 16, 2018, the Company and Immugenyx LLC, (“Immu”), which is engaged in the development of technology related to the production and use of humanized mice, entered into a Collaboration Agreement (the “Immu agreement”) pursuant to which the parties will collaborate in the funding of the continued development of, and commercialization of, the Immu technology. Pursuant to the Immu agreement, the Company and Immu entered into a loan agreement. During the quarter ended March 31, 2020, the Company advanced an additional $0.25 million under the loan agreement which was charged to expenses under ASC 730-10-50 and ASC 20-50 and presented as research and development costs.

The following extract is taken from Orgenisis' quarterly report dated 31 March 2020. This colaberation is very much still in play and simingly looking to be quite profitable with the patents granted within Europe for the Hu-PHEC treatments.

Hemogenyx Pharmaceuticals PLC.

As described in Note 12 to the financial statements of December 31, 2019, on October 18, 2018, the Company and Hemogenyx Pharmaceuticals PLC., a corporation with its registered office in the United Kingdom, and Hemogenyx-Cell, a corporation with its registered office in Belgium, and is engaged in the development of cell replacement bone marrow therapy technology (“H-Cell” and, collectively with the Company, “Hemo”), entered into a Collaboration Agreement (the “Hemo agreement”) pursuant to which the parties will collaborate in the funding of the continued development of and commercialization of, the Hemo technology via the Hemo group companies. Pursuant to the Hemo agreement, the Company and Hemogenyx LLC (“Hemo-LLC”) (a wholly owned USA subsidiary of Hemo), entered into a loan agreement. During the quarter ended March 31, 2020, the Company advanced an additional $0.25 million under the loan agreement which was charged to expenses under ASC 730-10-50 and 20-50 and presented as research and development costs.
14
Immugenyx LLC
As described in Note 12 to the financial statements as of December 31, 2019, on October 16, 2018, the Company and Immugenyx LLC, (“Immu”), which is engaged in the development of technology related to the production and use of humanized mice, entered into a Collaboration Agreement (the “Immu agreement”) pursuant to which the parties will collaborate in the funding of the continued development of, and commercialization of, the Immu technology. Pursuant to the Immu agreement, the Company and Immu entered into a loan agreement. During the quarter ended March 31, 2020, the Company advanced an additional $0.25 million under the loan agreement which was charged to expenses under ASC 730-10-50 and ASC 20-50 and presented as research and development costs.

The project at Nottingham "Data led synthesis: an undergraduate project in chemical optimisation" was set to last four weeks which started in late February. I would imagine they will mention the results of this with the release of the annual results.

This company will be on everyone's radar pretty soon.
It's rolled out in Leeds University and being trialed in a 4 week project by undergraduates at Nottingham University.
This coupled with the collaberation with AstraZeneca, for me, means Deepmatter will become a big player.

RNS Number : 0357M
Tiziana Life Sciences PLC
06 May 2020

TR-1: Standard form for notification of major holdings



NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

TIZIANA LIFE SCIENCES PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

MORRIS SILVERMAN

City and country of registered office (if applicable)

WINNETKA, ILLINOIS, USA

4. Full name of shareholder(s) (if different from 3.)v

Name

MS INVESTMENTS LLC

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

1 MAY 2020

6. Date on which issuer notified (DD/MM/YYYY):

1 MAY 2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.94%

NIL

4.94%

160,766,883

Position of previous notification (if

applicable)

3.63%

NIL

3.63%



8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORDINARY SHARES OF 3p EACH

GB00BKWNZY55

7,944,565

-

4.94%

-

SUBTOTAL 8. A

7,944,565

4.94%





B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
datex

Exercise/
Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1





B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
dat

There's a good amount of buys going through with the spread hiding them as sells.

With results due any day now I'm more than happy with my investment here and I'm continuing to add as I profit take from others.

Interesting

I think it's all about getting Lamellar listed so they can reap the rewards of the Covid buying frenzy when Lamellasome starts being used to treat Covid patients.

At what timestamp?